Possible Causes of Failing to Meet Primary Endpoints: A Systematic Review of Randomized Controlled Phase 3 Clinical Trials in Patients With Non–Small Cell Lung Cancer

被引：0
|
作者：
Mitsugu Ikeda
Tatsuya Ochibe
Masahiro Tohkin
机构：
[1] Nagoya City University,Department of Regulatory Science, Graduate School of Pharmaceutical Sciences
来源：
Therapeutic Innovation & Regulatory Science | 2019年 / 53卷
关键词：
phase 3 clinical trial; systematic review; non—small cell lung cancer; primary endpoint; success rate;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：324 / 331
页数：7
相关论文
共 50 条
  • [21] Meta-analyses of clinical trials in patients with non-small cell lung cancer
    Kovac, V
    Smrdel, U
    NEOPLASMA, 2004, 51 (05) : 334 - 340
  • [22] Study protocol: Systematic review and meta-analysis of randomized controlled trials in first-line treatment of squamous non-small cell lung cancer
    DeLozier A.M.
    Brown J.
    Natanegara F.
    Zhao L.
    Cui Z.L.
    Able S.L.
    Bowman L.
    Treat J.
    Hess L.M.
    Systematic Reviews, 3 (1)
  • [23] Reply to the comments on: Erlotinib in combination with bevacizumab has potential benefit in non small cell lung cancer: A systematic review and meta-analysis of randomized clinical trials
    Zhao, Binghao
    Zhang, Wenxiong
    LUNG CANCER, 2018, 126 : 225 - 226
  • [24] The efficacy of bevacizumab combined with platinum-containing chemotherapy in the treatment of advanced non-small cell lung cancer in China: a systematic review and meta-analysis of randomized clinical trials
    Han, Guangsu
    Li, Chenlu
    Yi, Ping
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [25] Incidence and risk of hypertension with bevacizumab in non-small-cell lung cancer patients: a meta-analysis of randomized controlled trials
    Chen, Jian
    Lu, Yingfeng
    Zheng, Yunliang
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2015, 9 : 4751 - 4760
  • [26] The efficacy of nivolumab for the treatment of advanced non-small cell lung cancer: a systematic review and meta-analysis of clinical trials
    Bao, Ming
    Pan, Yue-Jiang
    Wang, Ran
    Li, Sheng-Long
    Liang, Jie
    Yung, Jun-Ming
    Luo, Jia
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2017, 10 (01): : 153 - 161
  • [27] The safety and efficacy of tislelizumab, alone or in combination with chemotherapy, for the treatment of non-small cell lung cancer: a systematic review of clinical trials
    Sorkhabi, Amin Daei
    Zaredini, Mahta
    Fazlollahi, Asra
    Sarkesh, Aila
    Naseri, Amirreza
    Mousavi, Seyed Ehsan
    Nejadghaderi, Seyed Aria
    Sullman, Mark J. M.
    Kolahi, Ali-Asghar
    Safiri, Saeid
    BMC PULMONARY MEDICINE, 2023, 23 (01)
  • [28] Postoperative adjuvant chemotherapy in non-small-cell lung cancer - review of clinical trials with randomization
    Ploch-Glapinska, Malgorzata
    Zapedowska, Jolanta
    Krzakowski, Maciej
    ONCOLOGY IN CLINICAL PRACTICE, 2005, 1 (02): : 63 - 71
  • [29] Incidence and risk of infections associated with EGFR-TKIs in advanced non-small-cell lung cancer: a systematic review and meta-analysis of randomized controlled trials
    Wang, Yingtian
    Wang, Mingzhen
    Wang, Qiaoxia
    Geng, Zhiying
    Sun, Mingxiang
    ONCOTARGET, 2017, 8 (17) : 29406 - 29415
  • [30] Economic Evaluations of Immune Checkpoint Inhibitors for Patients with Non-Small Cell Lung Cancer: A Systematic Review
    Li, Na
    Zheng, Huanrui
    Zheng, Bin
    Chen, Chaoxin
    Cai, Hongfu
    Liu, Maobai
    CANCER MANAGEMENT AND RESEARCH, 2020, 12 : 4503 - 4518
12345